

Inhaled Fluticasone in Wheezy Infants

Submission date 07/11/2005	Recruitment status No longer recruiting	☐ Prospectively registered ☐ Protocol
Registration date 28/11/2005	Overall study status Completed	☐ Statistical analysis plan ☒ Results
Last Edited 07/01/2008	Condition category Respiratory	☐ Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Clare Murray

Contact details
North West Lung Research Centre
Wythenshawe Hospital
Southmoor Road
Manchester
United Kingdom
M23 9LT
+44 (0)161 291 4199
cmurray@fs1.with.man.ac.uk

Additional identifiers

Protocol serial number
N/A

Study information

Scientific Title

Acronym
IFWIN

Study objectives

1. Can the early introduction of inhaled corticosteroids (ICS) prevent the progressive fall in lung function seen in asthmatics?
2. Can early introduction of inhaled corticosteroids in children with asthma modify the natural history of the disease or prevent recurrence of asthma later in life?
3. Does treatment with ICS reduce symptoms in non-asthmatic wheezy children and improve their lung function at age 6 years?
4. Do inhaled corticosteroids improve the quality of life of families with wheezing children?
5. Is continuous treatment with ICS at this dose in young children associated with any local or systemic side effects?

Ethics approval required

Old ethics approval format

Ethics approval(s)

ERP/97/023, 21st April 1997

Study design

A randomized double blind placebo controlled study investigating the effects of early intervention with low dose inhaled corticosteroids (fluticasone propionate) in young children with wheeze

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Asthma in children

Interventions

Low dose inhaled corticosteroids (fluticasone propionate) versus placebo

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Fluticasone propionate

Primary outcome(s)

1. Occurrence of asthma at age 5 and 6
2. Lung function at age 5
3. Non-specific bronchial hyper-reactivity at age 5
4. Number of courses and total dose of add-on fluticasone propionate required

Key secondary outcome(s))

1. Rescue and added asthma medication
2. Number of exacerbations
3. Safety parameters length/height, weight
4. Symptom scores
5. Adrenal function

Completion date

31/03/2003

Eligibility

Key inclusion criteria

1. Children aged 6 months to 4 years
2. Two episodes of doctor verified wheeze or one episode continuous for more than 4 weeks

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Child

Lower age limit

6 months

Upper age limit

4 years

Sex

All

Key exclusion criteria

1. Pre-term less than 34 weeks gestation
2. Neonatal lung disease or other lung disease
3. Other chronic disease
4. Children already or previously used an inhaled corticosteroid
5. Children who cannot use the spacer device

Date of first enrolment

01/05/1997

Date of final enrolment

31/03/2003

Locations

Countries of recruitment

United Kingdom

England

Study participating centre
North West Lung Research Centre
Manchester
United Kingdom
M23 9LT

Sponsor information

Organisation
Wythenshawe Hospital (UK)

ROR
<https://ror.org/05vpsdj37>

Funder(s)

Funder type
Industry

Funder Name
GlaxoSmithKline (UK)

Alternative Name(s)
GlaxoSmithKline plc., GSK plc., GlaxoSmithKline plc, GSK

Funding Body Type
Government organisation

Funding Body Subtype
For-profit companies (industry)

Location
United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	Results	26/08/2006		Yes	No